Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments
ImmunoTargets and Therapy · 2024-05 · Volume 13 · 259-271
DOI: 10.2147/itt.s458800 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ImmunoTargets and Therapy, 2024-05. Verfasst von Fuyu Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disease characterized by the excessive proliferation of keratinocytes and heightened immune activation. Targeting pathogenic genes through small interfering RNA (siRNA) therapy represents a promising strategy for the treatment of psoriasis. This mini-review provides a comprehensive summary of siRNA research targeting the pathogenesis of psoriasis, covering aspects such as keratinocyte function, inflammatory cell roles, preclinical animal studies, and siRNA delivery mechanisms. It details recent advancements in RNA interference that modulate key factors including keratinocyte proliferation (Fibroblast Growth Factor Receptor 2, FGFR2), apoptosis (Interferon Alpha Inducible Protein 6, G1P3), differentiation (Grainyhead Like Transcription Factor 2, GRHL2), and angiogenesis (Vascular Endothelial Growth Factor, VEGF); immune cell infiltration and inflammation (Tumor Necrosis Factor-Alpha, TNF-α; Interleukin-17, IL-17); and signaling pathways (JAK-STAT, Nuclear Factor Kappa B, NF-κB) that govern immunopathology. Despite significant advances in siRNA-targeted treatments for psoriasis, several challenges persist. Continued scientific developments promise the creation of more effective and safer siRNA medications, potentially enhancing the quality of life for psoriasis patients and revolutionizing treatments for other diseases. This article focuses on the most recent research advancements in targeting the pathogenesis of psoriasis with siRNA and explores its future therapeutic prospects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
- Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People's Republic of China.
- Department of Rehabilitation, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
ORCID-Profile: Fuyu Zhao
Zitieren
APA
Zhao, F., Zhao, J., Wei, K., Jiang, P., Shi, Y., Chang, C., Zheng, Y., Shan, Y., Li, Y., He, B., Zhou, M., Liu, J., Li, L., Guo, S., & He, D. (2024). Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments. ImmunoTargets and Therapy, Volume 13, 259-271. https://doi.org/10.2147/itt.s458800
Vancouver
Zhao F, Zhao J, Wei K, Jiang P, Shi Y, Chang C, et al. Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments. ImmunoTargets and Therapy. 2024;Volume 13:259-271. doi:10.2147/itt.s458800
BibTeX
@article{Zhao2024,
author = {Zhao, Fuyu and Zhao, Jianan and Wei, Kai and Jiang, Ping and Shi, Yiming and Chang, Cen and Zheng, Yixin and Shan, Yu and Li, Yunshen and He, Bingheng and Zhou, Mi and Liu, Jia and Li, Li and Guo, Shicheng and He, Dongyi},
title = {Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments},
journal = {ImmunoTargets and Therapy},
year = {2024},
volume = {Volume 13},
pages = {259--271},
doi = {10.2147/itt.s458800}
}
EUVIMED